- 专利标题： IRIDINESULFONAMIDE COMPOUND AND USE METHOD THEREOF
-
申请号： EP17769433.8申请日： 2017-03-22
-
公开(公告)号： EP3444237A1公开(公告)日： 2019-02-20
- 发明人: ZHU, Li , YANG, Yanqing , DAI, Liguang , DUAN, Xiaowei , YANG, Zhao , ZHANG, Hui , HU, Yuandong , PENG, Yong , HAN, Yongxin , ZHAO, Rui , TIAN, Xin , WANG, Shanchun
- 申请人： Chai Tai Tianqing Pharmaceutical Group Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
- 申请人地址： No.369 Yuzhou South Road Haizhou District Lianyungang Jiangsu 222062 CN
- 专利权人： Chai Tai Tianqing Pharmaceutical Group Co., Ltd.,Lianyungang Runzhong Pharmaceutical Co., Ltd.,Centaurus BioPharma Co., Ltd.
- 当前专利权人： Chai Tai Tianqing Pharmaceutical Group Co., Ltd.,Lianyungang Runzhong Pharmaceutical Co., Ltd.,Centaurus BioPharma Co., Ltd.
- 当前专利权人地址： No.369 Yuzhou South Road Haizhou District Lianyungang Jiangsu 222062 CN
- 代理机构： Müller Schupfner & Partner Patent- und Rechtsanwaltspartnerschaft mbB
- 优先权： CN201610166113 20160322
- 国际公布： WO2017162156 20170928
- 主分类号： C07D203/24
- IPC分类号： C07D203/24 ; A61K31/396 ; A61P35/00
摘要：
An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceutically acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition thereof in treating IDH1 mutation- induced cancer.
公开/授权文献
- EP3444237B1 IRIDINESULFONAMIDE COMPOUND AND USE METHOD THEREOF 公开/授权日：2020-10-28
信息查询
